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ABSTRACT

Madan, Ashish. M.S.M.E., Department of Mechanical and Materials Engineering, Wright
State University, 2018. In vitro assessment of the effects of valvular stenosis on aorta
hemodynamics and left ventricular function.

Calcific aortic stenosis (CAS) is the most common valvular heart disease and is associated
with aortopathy and ventricular dysfunction. Hemodynamic alterations due CAS could
affect the aorta lining (endothelium), that is in direct contact with the blood, triggering
adverse biological responses that may possibly cause aortic dilation and dissection. Also,
CAS could impose excessive ventricular load leading to ventricular wall thickening, thus
putting an individual at a higher risk of heart attack or stroke. These pathophysiological
effects of CAS are highly dependent on the degree of calcification. However, the impact
of CAS development on aorta flow and left ventricular workload remains largely unknown.
Hence the objective of this study is to measure experimentally the effect of CAS on aorta
hemodynamics using particle image velocimetry; and left ventricular function in terms of
left ventricular work, at different stages of calcification. This study will provide insights
on aorta flow abnormalities and left ventricular overload, due CAS, which can be linked to
aortopathy and heart failure.
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CHAPTER 1:
INTRODUCTION
1.1

The Human Heart
The heart is the primary muscular organ of the cardiovascular system which acts

as a circulatory pump and helps in driving blood throughout the vasculature. The right
side of the heart pumps blood through the lungs where it gets oxygenated. This
oxygenated blood enters the left side of the heart, which supplies it to the rest of the
body.

1.1.1

Anatomy
The heart is divided into four chambers (Figure 1) [1]: the two atria (right and

left) and two ventricles (right and left) [2]. The atria and the ventricles are connected by
the atrio-ventricular valves (mitral and tricuspid valve), while the semilunar valves (aortic
and pulmonary valve) connect the ventricles to their respective attached arteries (Figure
1). The atrio-ventricular valves and the semilunar valves are responsible for maintaining
unidirectional flow throughout the cardiac cycle.

1

Figure 1:Schematic diagram of the heart. The arrows
represent the direction of the blood flow. De-oxygenated
blood from the right ventricle enters the lungs via the
pulmonary artery and gets oxygenated. Oxygenated blood
in the left ventricle is supplied to the e entire body via the
aorta.

1.1.2

Function
The cardiac cycle is divided into two phases: systole and diastole. During the

diastolic phase, (see Figure 2) the atrio-ventricular valves open and the blood flows
passively from the atria into the ventricles, filling up to 80% of their end diastolic
volume. The remaining 20 % is filled due to atrial contraction. The end of diastole is
marked by the closing of the atrio-ventricular valves. The systolic phase begins with
isovolumetric contraction of the ventricles with all the valves remaining closed. This
causes the pressure in the ventricles to rise above the pressure in the arteries. A negative
pressure gradient is generated across the semilunar valves causing them to open and
2

blood to flow to the arteries. At the end of systole, all the valves close, the ventricles
relax, and ventricular pressure progressively decreases back to 0 mmHg. The entire
cardiac cycle lasts for 0.86 seconds for a physiological heart rate of 70 beats every
minute.

Figure 2: Schematic showing heart valve function during systole and diastole

The left ventricle of the heart is responsible for supplying oxygenated blood to the
systemic circulation through the aorta. To achieve this, the left ventricle contracts,
creating a peak-systolic pressure of about 120 mmHg to overcome the resistance of the
systemic vasculature. Left ventricular function is assessed using two metrics: cardiac
output (CO) and ejection fraction (EF). CO is the amount of blood pumped by the heart
per minute. It is calculated as the product of the stroke volume and the heart rate [2]. EF
is a measurement of the percentage of blood that is ejected by the ventricle of its total
blood volume at each contraction. An adult human body has typically a CO of 5.0 L/min
and an EF of 60 % [2]
3

1.2

The Left Ventricle

1.2.1

Anatomy
The left ventricle ( Figure 3) [3] is one of the four chambers of the heart. It is

located in the lower left portion, below the left atrium. The left ventricular chamber is
connected to the atrial chamber via mitral valve, that regulates unidirectional blood flow
from the atrium into the ventricle. Since it supplies blood throughout the systemic
vasculature, the left ventricle has the most muscular walls of all the chambers [4]. The
left ventricular wall is three times thicker that right ventricular wall. It is separated from
the right ventricle by interventricular septum [5].
The left ventricle is longer and more conical in shape than the right [6]. The cross
section of its cavity is oval or nearly circular in shape. The inner surfaces of the left
ventricle feature irregular muscular columns called trabeculae carnea [5]. Out of the three
types of trabeculae carnea, the third type musculi papillares gives rise to chordae
tendinae. There are two musculi papillares, that are connected to the anterior and

mitral valve
chordae tendinea

aortic valve

papillary muscle
interventricular
septum
trabeculae carnea

Figure 3: Left ventricular anatomy. Figure shows cross section of the
left ventricle along the coronal plane.
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posterior wall of the left ventricle. The chordae tendinae arising from each of the
papillary muscle are further connected to both the cusps of the mitral valve (bicuspid

1.2.2

Function
The left ventricle undergoes contraction during the systolic phase and relaxation

during the diastolic phase of a cardiac cycle. As the left ventricle contracts, it pushes the
oxygenated blood through the aortic valve in to the AA and supplies blood to the
systemic vasculature. During the diastolic phase, the left ventricular muscles are relaxed
and allow for left ventricular filling with blood. The left ventricle generates a pressure of
120 mmHg at the peak systolic phase of the cardiac cycle.

5

1.3

The Aortic Valve

1.3.1

Structure and Function
The aortic valve (Figure 4) is located between the left ventricular outflow track

and the ascending aorta (AA). The function of the aortic valve is to allow unidirectional
flow between the left ventricle and the aorta. The normal aortic valve , also called
tricuspid aortic valve (TAV), is composed of three leaflets (left-, right- and non-coronary
leaflets), each attached to its respective sinus [7]. The sinus region consists of three
cavities through which originate the left- and right-coronary arteries. The leaflets derive
their respective names from these arteries [7], [8].
rightcoronary
leaflet

leftcoronary
leaflet

noncoronary
leaflet
Figure 4: Schematic of the aortic valve as seen from the
aorta
The leaflets consist of three different layers: the fibrosa (with circumferentially
aligned collagen fibers), the spongiosa (loose, watery connective tissue containing
glycosaminoglycans) and the ventricularis (with radially aligned elastin fibers intertwined
with collagen fibers) [7]–[9]. The fibrosa on the aortic side of the leaflets contributes in
resisting the tensile stress (Figure 5) [10] in the circumferential direction [11]. The
6

ventricularis is the ventricular side of the valve cusp and helps in reducing the radial
strains caused by the blood flow when the valve is open. [11]–[13]. The spongiosa lies
between the fibrosa and the ventricularis and functions as a lubricating interface between
the two other layers [10], [12].

Figure 5: aortic valve leaflet and its mechanical response during systole
and diastole (a) stress-strain plot for elastin and collagen fibers
throughout the cardiac cycle, (b) leaflet orientation during systole and
diastole
7

1.3.2

Hemodynamics
The dynamics of aortic valve leaflet is controlled by the transvalvular pressure

gradient established between the left ventricle and the aorta. The pressure in the aorta at
the end of diastole is around 80 mmHg. During the systolic phase, the left ventricle
generates a blood pressure of up to 120 mmHg, which creates a negative pressure
gradient across the aortic valve, causing the leaflets to open. As the ventricle relaxes, a
positive pressure gradient is created across the valve, causing the leaflet to close.

Figure 6: The left ventricular and aortic pressure
waveforms. The initial systolic phase is marked with
iso-volumetric ventricular contraction. A negative
transvalvular pressure gradient causes the aortic valve
to open, thus marking the beginning of ventricular
ejection. The systolic phase ends with ventricular
relaxation and closing of the aortic valve.

The aortic valve maintains a unidirectional blood flow with minimum resistance.
8

The blood flow behavior downstream of the aortic valve is highly dependent on the aortic
valve size or the effective orifice area (EOA). The EOA is the minimum cross-sectional
area of the jet emanating from the aortic valve. It is used to define the severity of valvular
stenosis.
As shown in Figure 6, the ventricular contraction and relaxation facilitates the
opening and closing of the aortic valve. Along with the pressure difference, the vortices
formed in the sinus region behind the aortic valve leaflets also facilitate the closing of the
valve cusps. Yoganathan et al. carried out an in vitro flow study through polymeric
valves in a left heart simulator and demonstrated that the flow structure downstream of
the aortic valve was characterized by a central orifice jet [14]. The results also
highlighted the existence of a vena-contracta, defined as a contracted portion of the jet
near the valve orifice. A flow separation region was observed downstream of the valve,
that caused reversed flow adjacent to the aortic wall. Additionally, vortices were
observed to be trapped within the sinus regions of the aorta model. The central orifice jet
had a maximum peak systolic velocity of 2.8 m/s.

9

1.4

Calcific aortic stenosis

1.4.1

Epidemiology and pathogenesis
Calcific aortic stenosis (CAS) is the most common valvular disease in the aging

population of the developed world. It is defined as a slow progressive disease with a
disease continuum that starts from mild valve thickening to severe calcification of the
leaflets. The initial stage of CAS, aortic sclerosis, is characterized by slow progression of
fibrocalcific remodeling and thickening of the valve leaflets, without any significant
obstruction to cardiac flow. Over the years, the disease progresses to severe calcification
causing impaired leaflet motion and serious obstruction to blood flow [15], [16].
In CAS, the valve leaflets become thick, stiff and covered with calcific nodules on
the fibrosa. The aortic valve orifice is narrowed with restricted motion of the leaflets, thus
obstructing blood flow [17]. A decrease in the valve orifice diameter leads to an
increased pressure gradient across the valve. This triggers the left ventricle to generate
more work to fulfill the excess of energy requirement [18], leading to progressive left
ventricle hypertrophy and heart failure [19]. Since the onset of CAS typically occurs in
the 6th or 7th decade of the human life, it was initially described as a degenerative disorder
due to leaflet wear and tear and passive calcium deposition [16], [20]. However, recent
histopathological and clinical studies have demonstrated the active nature of CAS [21],
by defining it as multifaceted disease condition involving lipoprotein deposition, chronic
inflammation, osteoblastic transition of valve interstitial cells and active leaflet
calcification [20].
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CAS is the third most common cardiovascular disease after coronary artery
disease and systemic arterial hypertension [15], [20], [22]. The disease can be
symptomatic or asymptomatic. The patients are likely to suffer from angina, syncope or
complete heart failure. Once these symptoms show up, it is difficult to predict the course
of the disease, and in severe conditions, patient death is likely to occur in a couple of
years [13]. CAS is a slow progressive disorder. About 1.8-1.9% of the patients suffering
from aortic sclerosis (initial stage) advance towards the latter stage of CAS, which is
aortic stenosis [23]. Hence, when compared with aortic sclerosis, the prevalence of aortic
stenosis (AS) is much lower. While 25% of the population above 65 years of age suffers
from aortic sclerosis, AS is found only in 1.7% of this population group [24]. In the
general population, the prevalence of AS is 0.4%. Of all the population suffering from
AS, a slight predominance of 2% was observed in men [20].
Population-based studies across the US and Europe have reported an increase in
the prevalence of CAS with an increase in age [21], [25]. According to the most recent
American Heart Association statistics, the prevalence of moderate and severe CAS
amongst population above 75 years is 2.8% [26].

1.4.2

Clinical management

1.4.2.1 Diagnosis
Symptoms of CAS are angina, syncope and shortness of breath. Physical
examination of patients with CAS have reported with a harsh systolic murmur. The onset
of these symptoms along with a systolic murmur indicate the presence of
hemodynamically significant aortic stenosis.
11

Echocardiography is an important diagnostic tool in determining the presence of
CAS [27]. It helps in identifying the severity of valvular obstruction [28], [29].
Echocardiographic images of stenotic valves have shown presence of calcific lesions on
the valve leaflets. Continuous wave doppler echocardiography helps evaluate the peak
blood flow velocities across the aortic valve [15] . Cardiac catheterization is another
diagnostic tool for the assessment of CAS. This technique evaluates the transvalvular
pressure gradient by simultaneously measuring left ventricular and aortic pressure, either
with single dual-lumen catheter or two separate catheters [30].
The severity of CAS can be determined by evaluating the effective orifice area
(EOA) of the aortic valve, jet stream velocity and transvalvular pressure gradient. The
following (Table 1) [31] classifies aortic stenosis based on guidelines provided by the
American Heart Association (AHA).

Table 1: Parameters and criteria for assessment of CAS severity
Jet Velocity

Avg. Pressure

(m/s)
Mild Stenosis
Moderate Stenosis
Severe Stenosis

EOA (cm2)

Gradient (mmHg)

<3.0

<25

>1.5

3.0-4.0

25-40

1.0-1.5

>4.0

>40

<1.0

12

The EOA of a stenosed valve is determined by using the Gorlin equation,
mathematically expressed as:

𝐸𝑂𝐴 =

𝐶𝑂
𝐻𝑅 ∗ 𝑆𝐸𝑃 ∗ 44.3 ∗ √∆𝑃

,

where CO is the cardiac output in ml/min, HR is the heart rate in beats/min, SEP is the
systolic ejection period in seconds per heart beat and ΔP is the transvalvular pressure
gradient in mmHg.

1.4.2.2 Treatment
To date, the management of aortic stenosis has been limited to the surgical
replacement of the aortic valve. Medical treatments have proved to be ineffective in
preventing or delaying the progression of the disease [10], [15], [30], [32]. Another
procedure to treat CAS is balloon valvotomy. Balloon valvotomy is a transcatheter
procedure in which a balloon is positioned within the aortic valve. The balloon is then
inflated causing an increase in the valve orifice area and improved leaflet mobility [30].
However, this method provides temporary relief, with patients showing signs of restenosis in 6-12 months and cannot be an alternative to aortic valve replacement (AVR)
[10]. Thus, balloon valvotomy is used in patients who are at serious risk for surgery and
waiting for an AVR [33].
Surgical intervention to replace the diseased aortic valve with a prosthesis has
proved to be an efficient treatment for CAS [27], [30]. Patients with post-AVR surgeries
have experienced a prolonged life with significant improvement in health [27]. A variety
13

of prosthetic valves have been designed in an effort to mimic the native aortic valve. In
an AVR surgery, the native aortic valve is first excised and then replaced with an
artificial valve by suturing it to the annulus. The choice of valve (mechanical or bioprosthetic) is highly patient-specific and depends on age, history of heart surgery, coexisting organ disease and a variety of other factors. The types of prosthetic valve are
discussed below.

•

Mechanical valve:
Mechanical valves have a longer lifespan as compared to bio-prosthetic valves.

Mechanical valves are found to last as long as 25 years and are less frequently replaced
when compared to bio-prosthetic valves [10]. There are three design types (Figure 7)
[13]: ball and cage, mono-leaflet and bi-leaflet. Ball and cage valves (Figure 7a) have a
ball made out of silicon, a circular sewing ring and a cage formed by three metal arches
[34]. The cage was initially made from Lucite which was later changed to Stainless Steel
and then Stellite 21. The sewing ring was made out of Teflon [13]. However, the ball and
cage design led to increased hemolysis due to the high amount of friction that existed
between the ball and the sewing ring. Thus, the ball and cage design is no longer used for
AVR. However, several thousands of patients still have these valves and require a follow
up [34].
The ball and cage design were replaced by the tilting disc valve (Figure 7b). The
single leaflet was secured by a lateral or central metal strut [34]. The disc opened at an
angle of 60⁰-80⁰ resulting in orifices of two different sizes. This valve was made from a
14

hemo-compatible material called pyrolytic carbon (PyC). However, it was prone to
design failure as the struts could not withstand the mechanical load during the closing of
the leaflet [13].
The most common mechanical valve design is the bi-leaflet mechanical valve
(Figure 7c). The bi-leaflet mechanical valve consists of 2 semilunar flaps made from PyC
that are hinged to a rigid valve ring [10], [35]. The leaflets open with a 75⁰-90⁰ angle
relative to the plane of the annulus. Once open, the two leaflets create three different
orifices: a narrow slit like opening located between the two leaflets when open, and two
large semicircular orifices on either side of the central opening. The bi-leaflet valve
design is associated with recirculation and increased levels of shear stresses that led to
hemolysis and thrombus formation [36]. As a result, patients with mechanical valves
require a lifetime anticoagulation therapy.

Figure 7: Different types of mechanical valves: (a) Ball and cage valve (StarEdwards); (b) tilting disc valve (Medtronic); (c) bi-leaflet valve (St. Jude)

•

Bio-prosthetic valve:

Bio-prosthetic valves (Figure 8) [13] are made of porcine tissue or bovine pericardium
and are designed to mimic the native aortic valve [34]. Bio-prosthetic valve are classified
15

as stented or stentless. A stented valve has a metal wire structure that is folded in a way
to form three spikes that act an attachment site for the commissures of the valve. The
entire wire frame is covered with Dacron to enable suturing of the tissue onto the stent
[10]. Stentless valves are manufactured from whole porcine aortic valves or from bovine
pericardium. These valves have improved valve hemodynamics as they provide a better

Figure 8: Bio-prosthetic valves: (a) Medtronic Hancock® porcine valve; (b)
Carpentier-Edward PERIMOUNT Magna Ease Aortic Heart Valve and (c)
Edwards Prima plus Stentless Porcine Bio-prosthesis [13]
EOA due to the absence of stent.
Unlike mechanical valves, bio-prosthetic valves do not lead to hemolysis or
thrombus formation and hence do not require anticoagulation therapy. However, they
have a shorter lifespan as they are prone to calcification and structural failure due to
mechanical stresses.

•

Transcatheter aortic valve replacement
Transcatheter aortic valve replacement (TAVR) (Figure 9) [37] is a minimally

invasive procedure used to replace a stenotic aortic valve [38]. About 33% of patients
above 75 years of age who are suffering from CAS are turned down for AVR surgeries as
surgical intervention is considered a potential risk for these patients [10]. TAVR is an
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option for the patients at risk from surgical AVR. In this procedure, a fully collapsible
replacement valve is delivered to the aortic valve site with the help of a catheter. The
catheter is inserted through the femoral artery or through the ribs from the apex of the left
ventricle. Once in position, the replacement valve is expanded by pushing the native
aortic valve out of the way [39].

Figure 9: Implanting transcatheter aortic valve through a femoral artery.
The catheter navigates through the arch of the aorta, once in place, the
fully collapsible valve expands and regulates the blood flow.

1.4.3

Aortic complications
The aorta (Figure 10) [40] is the largest artery that stems from the left ventricle

and extends all the way down to the abdomen [41]. It is divided into the thoracic aorta
and the abdominal aorta. The thoracic aorta is further divided into four parts: the aortic
root (which includes the aortic valve annulus, the aortic valve cusps and sinuses of
Valsalva), the ascending aorta, the aortic arch and the descending aorta [42]. The wall of
the aorta is composed of three layers: tunica intima, tunica media and tunica adventitia
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Figure 10: Sections of the thoracic and abdominal aorta.
[42]. The tunica intima is composed of endothelial cells, and this is the layer, in direct
contact of the blood. The tunica media consist of elastic fibers and smooth muscle cells.
The tunica adventitia is the outermost layer and mainly composed of collagen.

1.4.3.1 Aortic dilation
Aortic dilation (Figure 11) [43] is defined as an abnormal expansion of the aorta.
A normal diameter for the ascending aorta (AA) ranges between 20 and 37 mm [44]. The
size of the AA depends on age, sex and indexes of body size. An AA can be defined as
dilated if the diameter is 1.1 times the diameter of a normal aorta [44]. The incidence of
AA dilation is 5-10 patients per 100,000 patients with peak incidence between 60-70
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years of age [45]. The Centers for Disease Control and Prevention rank aortic dilation as
the 15th most common cause of death in patients above 65 years of age [46]. AA dilation
is of two types: symmetric and asymmetric. The symmetric pattern is associated with AA
of calcified TAV and is present in the mid-ascending aorta [47] . The expansion rate of
dilated AA ranges between 0.75- 1.1 mm/year. Aortic dilation if not addressed can lead
to dissection and rupture of the aorta.

Figure 11: Symmetric pattern of
aortic dilation in TAV AA.

1.4.3.2 Aortic dissection
Aortic dissection occurs when the inner layer of the aorta tears, causing the blood
to flow in between the tissue layers of the aortic wall. This results in abnormal pressure
over the aortic wall and may cause it to rupture. This is a potentially dangerous condition
that needs immediate medical attention.
19

Aortic dilation has been associated with aortic dissection. Numerous studies have
attempted to evaluate the risk of aortic dissection with the diameter of a dilated AA.
Aortic diameter of 5.5 cm or greater [42] was considered as a risk for aortic dissection,
however a clinical study involving 230 patients reports occurrences of rupture in dilated
AA with diameters less than 5.5 cm [48]. Hence it is important to monitor the progression
of aortic dilation. This can be done using imaging techniques such as computed
tomography (CT) scan and magnetic resonance imaging (MRI) [44].

1.4.3.3 Management
Management of aortic dilation involves taking preventive measure to avoid
dissection of the dilated aorta. This is achieved by surgical intervention or by using
minimally invasive techniques. Surgical treatment for aortic dilation involves an open
chest approach. It involves removal of the aorta tissue damaged due to dilation and
replacing it with a fabric tube, called graft [49]. An alternative for surgery is a minimally
invasive technique called endovascular repair for treating dilation [44]. In this technique,
a catheter with an expandable stent graft is inserted through one of the groin arteries and
is guided to the site of dilation with the help of X-ray images. The stent graft is allowed
to expand within the aorta, while the wireframe pushes against the healthy part of the
aorta sealing the graft in place [50]. The blood then flows through the graft and does not
come in contact with the dilated region of the aorta.

1.4.4

Left ventricular hypertrophy
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Left ventricular hypertrophy can be defined as an enlargement and thickening of
the myocardial mass [21], [51]. Aortic stenosis has been associated with left ventricular
hypertrophy [51]. In aortic stenosis, the reduced valve orifice, causes an obstruction to
the blood flow. To overcome this obstruction the left ventricle overworks to maintain the
cardiac output. This is achieved by an increase in ventricular pressure. The mechanical
signals generated by the elevated ventricular pressure initiates a cascade of biological
events that lead to an increase in cardiac mass [15]. Treatment for left ventricular
hypertrophy due to aortic stenosis involves replacement of the stenosed valve with an
artificial or tissue valve [51].

Figure 12: Figure shows sectional view of the heart with left
ventricular hypertrophy
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1.4.5

Evidence for a hemodynamic etiology

1.4.5.1 Aorta hemodynamics
Clinical findings have established a relation between aortic dilation and TAV
associated stenosis. More than half of the patients suffering from CAS also have a dilated
ascending aorta (AA) [52]. Mid-ascending aortic dilation in patients suffering from CAS
is now accepted as purely hemodynamic due to TAV stenosis [53], [54]. Crawford and
Roldan carried out a study that assessed the aortic root diameter of 118 patients suffering
from aortic stenosis. The study concluded that aortic root dilation is common in patients
with aortic stenosis. Another study assessed the rate of expansion in patients with poststenotic dilated AA that were submitted for AVR surgery. Ninety-three patients suffering
from isolated severe CAS along with dilated AA (50-60 mm) were involved in this study
[52]. AVR surgery was performed and the patients had a follow-up for about 10 years.
The follow-up was performed using CT scans and echocardiographic evaluations. During
the 10 years, there was no significant increase in the aortic dimensions with an average
expansion rate of 0.3 ± 0.2 mm/year [52]. Studies that have tracked post-stenotic aortic
dilation with no valve replacement, have reported rate of expansion 10 times the rate
being reported in this study [55], [56]. This study highlighted two major findings: 1) once
the hemodynamic conditions were corrected by replacing the stenotic valve, no further
expansion of the aorta was observed, 2) hemodynamic effect of valvular stenosis is the
reason for post-stenotic aortic dilation.
Turbulent flow is believed to cause a variety of pathophysiological effects.
Viscous Shear stresses due to turbulent flow are believed to cause damage to the intimal
surface of the blood vessels. The existence of turbulence in the aorta was demonstrated
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by a clinical study involving 15 people, that analyzed the flow in the AA of humans with
normal and diseased aortic valves [57]. The study highlighted that the maximum
turbulence was observed in AA of patients with aortic stenosis. Histological studies of
aortic wall from the post stenotic region have shown defective elastic elements and
extensive areas of increased fragility [54].
An in vitro study by Yearwood et al analyzed the flow in a human aorta model
using laser Doppler anemometer (LDA) [58]. In this study, aortic stenosis was modeled
using prosthetic aortic valves attached to an acrylic aorta model in a mock circulatory
system. Turbulent axial stresses determined in this study were found to increase
drastically with increased stenosis. Another in vitro study by Yoganathan et al, found
hemodynamics downstream of the stenosed aortic valve, to be dependent on the degree of
stenosis [59].
A recent clinical study using 4-D flow magnetic resonance imaging (Figure 13),
provided new insights on the effect of aortic stenosis on regional aortic wall shear stress
(WSS) [60]. Patients with moderate and severe stenosis, with an impaired valve opening
experienced increased velocities in the AA. For patients with mild aortic stenosis, a 57 %
increase in the WSS was observed in the outer proximal aorta, when compared with the
normal TAV patients. Further, elevation in WSS was observed in patients with moderate
and severe aortic stenosis (20-178%) when compared to patients with no stenosis. The
patient cohort of this study involved patients with RL-BAV (bicuspid aortic valve (BAV)
with left and right coronary leaflet fusion), NL-BAV (BAV with left and non-coronary
leaflet fusion), TAV, and their stenosed counterparts with degrees of stenosis, ranging
from mild -severe. This study highlighted that the variability and magnitude of 3D WSS
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patterns is significantly higher in patients with aortic stenosis, irrespective of the valve
phenotype. This study contradicts the previous findings that aortic stenosis did not
elevate WSS [61], by demonstrating a significant increase in aortic 3-D WSS in the
presence of aortic stenosis for both BAV and TAV groups.

Figure 13: WSS analysis using 4-D MRI. Figure shows elevated WSS in AA
with stenosed aortic valves
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Elevated WSS has been previously related to pathogenic vascular remodeling that
leads to aneurysm [62]. Thus, all of these clinical, imaging, in vitro and in vivo studies
seem to provide compelling evidence for a possible role of hemodynamics in poststenotic AA dilation.

1.4.5.2 Calcified valve hemodynamics
In vitro experiment, assessing the effect of varying degrees of aortic stenosis on
pulsatile valvular flow, was conducted by Bluestein et al. using laser doppler
anemometry (LDA) [63]. The study was conducted using polyurethane valves. The
different degrees of stenosis were mimicked by gluing the leaflets together, to generate a
smaller orifice. The results demonstrated a noticeable effect of aortic stenosis on the
velocity profile with elevated turbulence level when compared to that of normal aortic
valve.
Another flow visualization study using PIV was conducted to analyze the flow
differences downstream of a normal and calcified aortic valve [64]. High orifice jet
velocity and regions of increased viscous stresses accompanied by high turbulence
downstream of the calcified valves were observed. With increased velocities observed at
peak systole in calcified valves, high magnitudes of vorticity were observed between the
sinus wall and the leaflets.
A computational study using fluid structure interaction modeling has compared
the flow generated by normal and calcified aortic valve (Figure 14) [65]. The healthy
model of the aortic valve generated a peak systolic velocity of 1.57 m/s, while the
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narrowed valve orifice in the calcified valves, led to an increase in peak orifice velocity.
A significant difference was observed in the transvalvular pressure gradient, as the
severely calcified valve model exhibited a 305% increase relative to the healthy model.
The WSS on the leaflets was also maximum for severely calcified model.

Figure 14: Figure shows the velocity contours, velocity streamlines and velocity vectors for
healthy, calcified and severely calcified valve models

A clinical study evaluated the relation of left ventricular hypertrophy with systolic
dysfunction and heart failure, in patients suffering from aortic stenosis [66]. It involved
137 patients with aortic stenosis undergoing pre-operative echocardiography and cardiac
catherization. The findings of this study suggest that left ventricular hypertrophy
promotes adverse cardiac consequences and provides a pathway towards heart failure in
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aortic stenosis.

1.5

Knowledge gap and research questions

1.5.1

Hemodynamic etiology of CAS
CAS has emerged as an active multifaceted disease condition whose triggers

include hemodynamic, cardiovascular and mechanical factors [67]–[69]. Studies indicate
that abnormal hemodynamics in the vicinity of aortic valve, experienced by the valve
leaflets cause tissue inflammation, which can lead to calcification and aortic valve
stenosis [70] .
The partial opening of the aortic valve due to stenosis could generate
hemodynamic alterations downstream of the valve resulting in a chaotic and turbulent
flow in the ascending aorta. The aorta lining in direct contact with the blood, tunica
intima, is composed of endothelial cells (EC). EC are highly sensitive to hemodynamic
forces and alteration in the blood flow environment have caused cell deformation,
realignment and inflammation [71]. These altered biological responses due to changes in
the hemodynamic environment have eventually led to aortic wall remodeling and dilation
[71], [70], [72], [73]. These etiologies have been supported by studies that have
demonstrated the impact of altered hemodynamics on valvular and aortic tissue [70],
[74]–[77].
The aortic valve stenosis also creates an obstruction to the blood flow during the
ventricular ejection. To overcome this obstruction and maintain the cardiac output, the
left ventricle systolic pressure increases subjecting the ventricle to an overload. This
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increase in ventricular pressure to maintain the left ventricular ejection performance,
initiates a surge of biological events, that ultimately lead to hypertrophy of the cardiac
muscle and myocardial fibrosis [15]

1.5.2

Rationale for this study
As suggested in vivo, CAS could cause downstream flow alterations giving rise to

abnormal hemodynamics. The hemodynamic theory of CAS asserts that this altered
hemodynamics in the AA could cause abnormal biological responses, affecting the
intimal surface of the aortic wall which can lead to aortic dilation and dissection. To
validate this theory, there is a need to investigate the degree to which aorta
hemodynamics is altered due to aortic valve stenosis. This study aims to assess the
isolated impact of the different degrees of valvular stenosis on aorta hemodynamics.
The obstruction to the blood flow due to narrowing of the valve in CAS, affects
left ventricular function. To overcome this increased resistance to blood flow, the left
ventricle performs additional work to maintain a physiological cardiac output. This
overload causes adverse cardiac consequences in the form of ventricular hypertrophy,
increase in ventricular mass that eventually lead to heart failure. Hence it is necessary to
quantify the amount of overload imposed by valvular stenosis on the left ventricle. This
study investigates the effect of varying degrees of valvular stenosis on left ventricular
overload.
Many studies have assessed the impact of stenosis on aorta hemodynamics. In
vitro study using LDA [63] assessed the impact of stenosis on aorta flow. However, the
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study incorporated polyurethane valve models and a non-compliant aorta model, which
could not generate native valve hemodynamics. Also, stenosis was modelled using glue
lesions which questioned the accuracy of the results. To mimic the native valve
hemodynamics another LDA study [78] used bio-prosthetic valves to assess the effect of
valvular stenosis on aorta flow. However, the aorta model used was heavily simplified as
a straight cylindrical non-compliant conduit. Lastly, PIV studies have assessed the impact
of valvular calcification on the flow in the sinus region using porcine tissue valves [64],
and the effect of congenitally defective valves on flow in AA [79], but the impact of
calcific aortic stenosis on flow in the AA remains largely unknown.
Clinical flow visualization technique such as MRI is able to measure wall shear
stress abnormalities caused by valvular stenosis in the AA [60]. However, most MRI
studies have been performed in patients with pre-existing AA dilation, preventing the
isolation of the effects of valvular stenosis on AA hemodynamics. Limited spatial
resolution is another drawback of PC-MRI. Computational studies allow higher spatial
resolution. However, these studies have significant simplification in terms of geometry
and cannot assess the impact of turbulence on the flow field.
Clinical studies have associated ventricular overload due to valvular stenosis to
ventricular remodeling and hypertrophy [66], [80]. However, the amount of overload
imposed on a ventricle due to a stenosis has not been quantified.
Therefore, this study aims at providing insights on the isolated impact of valvular
stenosis on ascending aortic flow using a non-dilated compliant silicon aorta model and
left ventricular function
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CHAPTER 2:
SPECIFIC AIMS
CAS is the most prevalent type of heart valve disease and is characterized by the
formation of calcific nodules on the valve leaflets, resulting in the narrowing of the valve
orifice. Valvular stenosis is associated with two cardiovascular complications: aortic
dilation and left ventricular hypertrophy. The hemodynamic theory of valvular stenosis
infers that the structural changes in the valve generate flow abnormalities downstream of
the valve in the AA. These altered hemodynamics could affect the aorta lining in
immediate contact with the blood surface (endothelium), triggering adverse biological
responses [73] and compromising the structural integrity of the aortic wall which could
possibly lead to aortic dilation and dissection [81]. Therefore, it is necessary to determine
the extent to which the varying degrees of stenosis alter the hemodynamics in the
ascending aorta. CAS causes reduced valve orifice. The narrowing of the aortic valve can
possibly create serious blockage to the blood emanating from the left ventricle. To
overcome this obstruction and maintain a physiologic cardiac output, the left ventricle
has to work harder thus experiencing an additional workload. This increase in ventricular
overload may lead to the thickening of the muscle wall and increase in ventricular mass.
This condition is defined as left ventricular hypertrophy, which puts an individual at a
higher risk for a heart attack or stroke. Hence it is important to assess the degree to which
valvular stenosis creates additional workload on the left ventricle.
2.1

Hypothesis and Objective:
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The hypothesis of this study is that structural changes in the aortic valve due to
CAS can cause abnormal hemodynamics in the aorta and left ventricular overload. The
magnitude to which aorta hemodynamics and ventricular load is altered, highly depends
on the degree of valvular stenosis. Hence the objective of this study is to experimentally
quantify the impact of valvular stenosis on aorta hemodynamics and left ventricular
function in a degree dependent manner. This objective is addressed through three specific
aims. Aim 1 describes the design of an experimental left-heart simulator and setup of a
flow visualization technique called particle image velocimetry (PIV), required to
investigate the hypothesis. The other two aims address the hypothesis through their
respective objectives: to evaluate the impact of valvular stenosis on aorta hemodynamics
(aim 2) and left ventricular function (aim 3).

2.2

Specific Aim 1: To design an in vitro setup that mimics a physiological flow

in the left side of the heart and captures the flow using PIV.
The objective of this aim was to design a setup that allowed the assessment of the
hemodynamic environment downstream of porcine aortic valve models in the AA. The
flow on the left side of the heart is pulsatile due to the periodic contraction and relaxation
of the left ventricle. Hence a pulsatile flow loop was needed to replicate the physiological
ventricular and aortic pressures (0-120 mmHg, 80-120 mmHg) and cardiac output (5.0
L/min). The flow loop designed was validated against physiological aortic pressure and
flowrate waveforms. A flow meter and pressure transducers allowed measurement of
flowrate and ventricular and aortic pressures. Flow analysis was done using PIV. The
PIV setup included a laser to illuminate the flow field of interest and a high-speed camera
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to capture images.

2.3

Specific Aim 2: To assess the effect of valvular stenosis on aorta
hemodynamics.
In this aim, PIV was used to capture velocity flow fields downstream of the valve,

near the sino-tubular junction as well as the AA. Velocity flow fields were captured at 43
phases of the cardiac cycle and ensemble averaging was done over 100 cardiac cycles at
each phase. Along with the velocity flow field, vorticity, viscous shear stress, Reynolds
shear stress and turbulent kinetic energy were evaluated from the velocity fields to
compare aorta hemodynamics downstream of a normal TAV tissue model and two
stenotic models mimicking moderate and severe calcification.

2.4

Specific Aim 3: To assess the effect of valvular stenosis on left ventricular
function.
This aim tries to evaluate the impact of the degree of valvular stenosis on the

overload imposed on the left ventricle to maintain a physiologic cardiac output. Left
ventricular work was evaluated by measuring pressure-volume relationships during the
ejection phase for the normal TAV and the two stenotic models.
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CHAPTER 3:
MATERIALS AND METHODS
3.1

Flow loop description
A flow loop was constructed to mimic the hemodynamics of the left side of the

heart. At 70 beats per min with a cardiac cycle 860 ms long, the flow conditions expected
were pulsatile and periodic, with a desired flow rate at a given instant of time ranging
between -5 to 20 L/min and a cardiac output (CO) of 5 L/min. The pulsatile flow loop
consisted of a bath chamber, a flow meter, a compliance and resistance units and a
reservoir (Figure 15). The flow was driven by a pulse generator that delivered
compressed air (25 psi) to a diaphragm accumulator (AD140B25T9A1, Parker Hannifin,
Cleveland, OH) mimicking the left ventricle (Figure 16). The operation of the ventricular
chamber was controlled by a 2-position 3-way solenoid valve (56C-13-111CA, Mac
Valves, Wixom, MI). The opening and closing of the solenoid valve was timed using a
square wave signal generated by a LabVIEW (National Instruments Corp., Austin, TX)
virtual instrument (VI). Unidirectional flow through the loop was achieved by installing a
mechanical valve in the mitral position upstream of the ventricular chamber, and a
porcine aortic valve downstream of the ventricular chamber.
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Figure 15: Pulsatile flow loop with PIV setup. (a) schematic of flow loop
highlighting all its components and (b) picture of laboratory setup of the flow
loop.
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Figure 16: Diaphragm accumulator
mimicking left ventricular function.

A fluid reservoir (volume: 4 L) placed between the resistance unit and the mitral
valve functioned as the left atrium and supplied fluid to the ventricular chamber during
diastole. Resistance and compliance units were used to achieve desired control over the
pressure and flow conditions. Compliance is defined as the ability of a blood vessel to
distend and increase in volume with increase in pressure. Mathematically, compliance C
can be quantified as
𝐶=

𝛥𝑉
,
𝛥𝑃
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where 𝛥𝑉 is the change in the arterial volume and 𝛥𝑃 is the change in the arterial blood
pressure. The compliance chamber (Figure 17) was a cylindrical chamber consisting of a

Figure 17: Compliance chamber
piston that controlled the ratio of air to fluid inside the chamber.

A gate valve (Figure 18) was used to generate vascular resistance and to control
mean arterial pressure (MAP). The systemic vascular resistance (R) is the resistance to
the blood flow created by the systemic vasculature. It can be defined mathematically
using the Hagen-Poiseuille flow theory as
𝑅=

𝛥𝑃
,
𝑄

where ΔP is the change in the time averaged pressure across an arterial segment and Q is
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the averaged arterial flow rate.

Figure 18: Gate valve used to control systemic
resistance

Piping used in the pulsatile loop was constructed using PVC and silicon tubing.
Two pressure transducers (P55D Validyne Engineering Corp., Northridge, CA) were
used to measure the aortic and ventricular pressure. The instantaneous flow rate
generated by the loop was measured by an ultrasonic flowmeter (ME-19-PXN,
Transonic, Ithaca, NY) installed downstream of the ventricular chamber. The flow loop
was tuned using the compliance and resistance units until a physiological cardiac output
of 5.0 L/min and an approximate value of aortic pressure was achieved.
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Figure 19: Figure showing components of the flow loop. (a) ultrasonic flowmeter (b)
pressure transducers on the aorta and the ventricular side (c) data acquisition board

The pressure transducers (Figure 19b) and flow meter (Figure 19a) generated
voltages which were analyzed by their respective modules. These modules sent analog
signals to a Data Acquisition Board (DAQ) (National Instruments Corp., Austin, TX)
(Figure 19c). A digital signal was generated by the DAQ board to monitor the pressure
and flow rate waveforms in real time using a secondary VI. This VI also recorded the
time history of instantaneous flowrate, and ventricular and aortic pressures. The flowrate
and pressure values obtained were ensemble averaged.
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3.2

Test section

The porcine aortic valve was placed into a valve chamber made of acrylic with
flat external walls to minimize refraction of the incident laser sheet. The chamber
consisted of an idealized three-lobed sinus geometry and a straight cylindrical conduit
(inner diameter: 24mm, length: 20 mm) mimicking the proximal section of the ascending
aorta. Pressure transducers were installed into two ports placed 24 mm upstream and 24
mm downstream of the aortic valve sinus, measuring the aortic and ventricular pressure
respectively. The valve chamber was connected to a compliant silicone aorta model. The
aorta geometry (Medisim Corp. Inc., Alton, ON) was 3D printed using a silicone
material. The aorta model and the valve chamber were submerged in a rectangular bath
chamber (Figure 20), filled with a solution of water and glycerol (BDH1172 VWR
ANALYTICA) (water: 60% and glycerol: 40%, by volume). The properties of this
solution (density: 1060 kg/m3, dynamic viscosity: 3.8 cp) approximated the properties of
blood (density: 1060 kg/m3, dynamic viscosity: 3.5 cp) and provided partial index
matching (refractive index: 1.39) with silicone (refractive index: 1.41) and acrylic valve
chamber (refractive index: 1.49).
The bath chamber featured an inlet port that connected to the inlet of the
rectangular conduit and an outlet port that connected to the outlet of the aorta model. The
rectangular conduit connected to the inlet of the valve chamber
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Figure 20: Figure of the bath chamber showing the valve chamber
connected to the compliant silicone aorta, and the two pressure
transducers used to measure aortic and ventricular pressures.

3.3

Valve models
Three aortic valve models were constructed for this study: a normal TAV

model (nTAV) and two stenotic models mimicking moderate (mTAV) and severe
(sTAV) calcification. Porcine hearts were obtained from a local slaughterhouse
(Copey’s Butcher House, Medway, OH) and were transported to the laboratory in icecold phosphate buffered saline (PBS). Upon arrival, the valves were excised from the
hearts and were kept moistened via frequent application of PBS solution. Excision
consisted of separating the valve from the base of the aorta. The following step
consisted of removing the excess ventricular muscle around the sinus region and
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suturing the valve on the circular supporting base plate of the valve mount. To
maximize optical access to the valve, the sinus wall was surgically removed without
damaging the valve leaflets. All experiments were conducted within 48 hours of
procuring the organ.

3.3.1

Normal TAV model
The normal TAV (nTAV) model (Figure 21) was constructed by removing the

excess muscle around the valve annulus. The valve was fixed on the circular shaped
valve mount using surgical sutures. The valve posts assisted in keeping the commissures
in place and maintain the leaflet orientation.

Figure 21: Figure shows (a) a normal TAV (nTAV) sutured on the
valve mount, (b) circular metallic valve mount.
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3.3.2

Calcified TAV models
Calcified valve models (Figure 22) were fabricated to replicate moderate and

severe calcification via partial commissural fusion. Once the valve was placed onto its
circular mount, partial commissural fusion was achieved by suturing together the adjacent
edges of the leaflets. The two degrees of stenosis were obtained by suturing the leaflets

Figure 22: Pictures of stenosed valve models. (a)
mTAV and (b) sTAV models. Picture also
highlights the variation in the placement of sutures
over the leaflets to mimic different degrees of
stenosis.
over a length of 4 mm (mTAV) and 8 mm (sTAV) away from the valve posts towards the
leaflet tip, respectively.

3.4

Particle Image Velocimetry
Particle Image Velocimetry (PIV) is a flow visualization technique that measures

instantaneous velocity flow fields by recording images of suspended seed particles in the
flow at successive instants of time (𝑡) and ( 𝑡 + ∆𝑡). The layout of a PIV setup is shown
in Figure 23. The first step in PIV is to seed the working fluid with tracer particles. A
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pulsed light source and its necessary optics used to generate a thin sheet of laser
illuminates a cross-section of the flow while a camera captures image pairs at a given
frequency. Software and electronic equipment helps to synchronize the pulsing of the
laser with the frame rate of the camera.

Figure 23: Schematic showing setup and functioning of PIV.

In PIV, the velocity of the flow field is extracted from the motion of the tracer
particles. The velocity is calculated indirectly, by measuring the displacement of the
tracer particles in a time interval ∆𝑡 between the two successive image pairs. However,
the displacement of the particles is not calculated on a single particle level, the flow field
of interest is divided into smaller sections called interrogation regions or windows. The
interrogation window is the region where cross-correlation is performed.
The images captured by the camera in PIV are greyscale digital images. The gray
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level for the camera sensor is defined using bits, and the number of levels per pixel are
evaluated as 2𝑏𝑖𝑡 . In general, particle images are grayscales with a wide range of
intensities (256 for an 8 bit camera, 65536 for a 16 bit camera). These intensity values of
each pixel, from the first and the second image of the image pair, are used to perform
cross-correlation.
The flow velocity is evaluated at equidistant grid points in PIV. The interrogation
window is centered on these grid points. Once the interrogation region is defined, the
displacement function of the tracer particles outlining the motion of the particles from the
first image (time 𝑡) to the second image (time 𝑡 + ∆𝑡) is calculated by a cross-correlation
technique. The correlation value is evaluated by the number of overlapping particle in the
spatially shifted image [82]. The location of the highest correlation value in the
correlation plane, is interpreted as the mean displacement of the particles in that region.
Direct cross-correlation is expensive in terms of required computing power. Hence, the
correlation is done using efficient fast Fourier transform (FFT) algorithm.
The average velocity is then evaluated by dividing the mean displacement of the
particles by the time interval ∆𝑡 between the two consecutive images. Once the velocity
is evaluated, the center of the interrogation window is shifted to the next grid point, thus a
two-dimensional velocity field is obtained.
The size of the interrogation window plays an important role in the PIV
measurements. The reliability of the cross-correlation method is highly dependent on the
number of overlapping particles that exist between the two interrogation windows,
centered on the same grid point of the image frames taken ∆𝑡 apart. A small number of
overlapping particles questions the accuracy of the mean displacement evaluated. Hence
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to maximize the accuracy of the measurements, an overlap is introduced between two
consecutive interrogation windows. Overlap determines the grid of the velocity vector or
the distance between the two adjacent velocity vectors. Overlap improves spatial
resolution. PIV studies conducted have shown that a 50% or 75% overlap is common
[82] [83].
Advanced evaluation methods have been incorporated to improve the accuracy
and resolution of the PIV results. PIV images can now be evaluated using a multi-pass
algorithm. In this method, an initial estimate of particle displacement is provided by a
large size of interrogation window. This estimate is used to displace or deform the
interrogation region used in the next pass. This technique allows to deviate from the
quarter rule (all displacements should lie within 1/4th of the interrogation window size),
thus providing the use of a smaller interrogation window size and improved spatial
resolution.

3.4.1

Tracer particle deposition speed
The assumption that particles passively follow the flow is incorrect, since the

particles are subjected to unsteady flow effects and can possibly have a velocity relative
to the flow. Hence it is necessary to evaluate the deposition velocity of the tracer particles
used in the PIV setup. This can be done using the Stoke’s settling velocity of the particles
given by:
𝑣max =

2 2 𝜌𝑝 − 𝜌𝑓
𝑟 (
) 𝑔,
9 𝑝
𝜇

where 𝑟𝑝 is the particle radius, 𝜌𝑝 is the particle density, 𝜌𝑓 is the fluid density, 𝜇 is the
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dynamic viscosity of the fluid and 𝑔 is the acceleration due to gravity. The particles used
in this study had a diameter of 11.7 μm and a density of 1100 kg/m3. The density of the
working fluid was 1060 kg/m3 and viscosity of 3.8×10-3 kg/m.s. The acceleration due to
gravity was taken as 9.81 m/s2. Thus, the tracer particle deposition speed evaluated was
0.785 μm/s

3.4.2

PIV setup
PIV system was incorporated into the pulsatile flow loop to capture the velocity

field in the mid-planes of the sinus and the ascending aorta regions. The tracer particles
selected were neutrally buoyant hollow glass microspheres (Sphericel 110P8, Potters
Industries LLC., Malvern, PA); with and average diameter of 11.7 µm and density 1100
kg/m3. The PIV system (Flowmaster, LaVision, Goettingen, Germany) incorporated a
double-head Nd:YAG laser (Nano S 30-30 PIV, Litron Lasers, Rugby, England) which
generated a pulsed output laser beam (wavelength: 532 nm; max output: 300 mJ; pulse
duration: 4ns). For each valve model, the laser sheet was positioned to illuminate two
sections of the flow through the laser access window situated on the bath chamber. Laser
position 1 was defined as the middle horizontal cross-section of the valve chamber, while
laser position 2 illuminated the middle cross-section of the AA model (see Figure 24).
The flow in the aorta was measured in two non-aligned planes so that maximum field of
view could be attained in both regions of interest. The two sections of the flow were
separated by a 10-mm thick stainless-steel block connecting the aorta phantom to the
valve chamber. The optical access was blocked for this section of the flow. For each laser
position, the camera was placed perpendicular to the laser sheet. Images at these two
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positions were captured by Imager sCMOS camera (LaVision, Goettingen, Germany),
resolution of 2560 × 2160, using AF Micro Nikkor 60 mm lens (Nikon Inc., Melville,
NY) and narrow band pass filter (532 ± 10 nm). The camera was used to capture a 62 ×
47 mm section of the flow. Image acquisition was performed by dual-channel frame
grabber, dual processor 64-bit, and 2.40 GHz computer. Image pairs were captured at 43
phases of the cardiac cycle for each valve model and laser position. For each phase of the
cardiac cycle, 100 image pairs were captured. A time filter was applied to remove
unsteady laser light reflections by subtracting the minimum intensity. A sliding
background was subtracted to overcome the intensity fluctuations in the background. This
provided an image with constant background level without affecting the particle signal to
be corelated. The vector filed calculated is associated with spurious or false vectors.
These spurious vectors were removed using median filter. In order to capture the
variations of the average flow field, ensemble averaging was performed on these 100
image pairs at each phase. The ∆ 𝑡 between the two image pairs was adjusted in such a
way that the maximum average displacement of the particle was approximately 25% of
the size of the smallest interrogation window (32 × 32 pixels).
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a

b

Figure 24: Figure shows flow fields captured and the respective laser and camera
positions used to capture (a) camera and laser positions to capture flow
characteristics in the proximal and the distal AA region (b) schematic of the flow
filed of interest.

The VI allowed to introduce a delay between the opening of the solenoid valve
and the trigger that controlled the firing of the laser. This allowed to capture phase-locked
PIV images that enabled to measure flow field velocity at specific phases of the cardiac
cycle (acceleration, peak systole, deceleration and diastole). Cross-correlation was
performed using the commercial PIV software Davis 8.3 (LaVision). A multi-pass
scheme was implemented with an initial interrogation window of 64×64 pixels and a final
interrogation window of 32×32 pixels. A 50% overlap was introduced between each
window to improve spatial resolution and limit in-plane particle loss.
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3.5

Uncertainty Analysis
An uncertainty analysis validates the PIV measurements by calculating the

difference between actual and the measured values. PIV uncertainty can be divided into
two different categories: systemic or bias uncertainties and random uncertainties.
Systemic uncertainty or bias uncertainty is a fixed uncertainty associated with a specific
system. The bias uncertainty is associated with peak-locking or pixel-locking
phenomenon. Pixel locking will occur when the size of the particle image diameter is
relatively smaller when compared to the size of the pixel in the camera, causing the
velocity to be strongly biased towards the integer-pixel values. This pixel locking effect
is unacceptable if the size of the particle image diameter is less than one-pixel unit. To
keep the pixel locking effect to a minimum, a widely accepted particle image diameter is
of two pixels. Also scientific complementary metal-oxide semiconductor (sCMOS)
cameras have small pixel diameter of 5-10 μm. Random uncertainty is variable and can
be estimated using repeated measurements. The typical causes of random uncertainty are:
noise or cycle-to-cycle variations. This noise can be evaluated by calculating the mean
velocity and standard deviation from ensemble averaged date sets. The random
uncertainty is inversely proportional to the square root of the number of measurements,
thus it is necessary to obtain adequate sample size to reduce the random uncertainty.

3.6 Hemodynamic Characterization
The in-plane instantaneous velocity fields (𝑢: axial component, 𝑣: transverse
component) obtained by cross-correlation were first filtered to eliminate erroneous
velocity vectors and then ensemble-averaged over 100 cardiac cycles to yield an average
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velocity field (𝑢:
̅ mean axial component, 𝑣̅ : mean transverse component) at each phase.
All subsequent analyses were performed in Tecplot 360 (Tecplot Inc., Bellevue, WA).
The axial and transverse components of the velocity fluctuation field (𝑢′ and 𝑣′) were
obtained from Reynolds decomposition, by subtracting the average velocity components
from the instantaneous velocity components:
𝑢′ = 𝑢 − 𝑢̅,

𝑣 ′ = 𝑣 − 𝑣̅ ,
Vorticity, viscous shear stress, Reynolds shear stress and turbulent kinetic energy
were used to characterize the flow fields generated by the valve models were evaluated
using Tecplot 360 as:

𝜔
̅=

𝜕𝑣̅ 𝜕𝑢̅
−
,
𝜕𝑥 𝜕𝑦

𝜏̅ = 𝜇 (

𝜕𝑢̅ 𝜕𝑣̅
+
),
𝜕𝑦 𝜕𝑥

′𝑣 ′,
̅̅̅̅̅̅
𝜏 ′ = 𝜌𝑢

and

𝑇𝐾𝐸 =

1 ̅̅̅̅2 ̅̅̅̅2
(𝑢′ + 𝑣′ ),
2
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respectively, where 𝜌 is density of blood and 𝜇 is the dynamic viscosity, and the overbar
denotes an ensemble averaged quantity.

3.7

Left ventricular overload characterization
To calculate the left ventricular overload, a pressure-volume curve was plotted for

each valve model. The pressure value for the ejection phase was obtained from the VI,
while the corresponding change in the ventricular volume was evaluated from the
instantaneous flowrate waveform. The area under the flow rate curve for the ejection
phase (Figure 25), was evaluated to measure ventricular volume. This was done by
dividing the area into trapezoids with the two parallel sides separated by a time step ∆𝑡,
thus evaluating the change in the volume. The expression used to evaluate the change in
volume:

𝛥𝑉 = 0.5 × (𝐹𝑙1 + 𝐹𝑙2 ) × 𝛥𝑡,

where 𝛥𝑉 is the change in ventricular volume, 𝛥𝑡 = 𝑡2 − 𝑡1 , 𝐹𝑙1 and 𝐹𝑙2 are the
corresponding flowrates at time 𝑡1 and 𝑡2 . The sum of all the 𝛥𝑉 throughout the ejection
phase ultimately provides the total ventricular volume

51

Figure 25: Schematic of the flow rate ejection phase, divided into trapezoidal
shaped areas to measure change in the ventricular volume

Once the P-V graph was plotted, the ventricular work was evaluated in Joules by
calculating the area under the P-V curve using trapezoidal rule. The expression for work
for a change in ventricular volume 𝛥𝑉 :

𝑉𝑒𝑛𝑡𝑟𝑖𝑐𝑢𝑙𝑎𝑟 𝑤𝑜𝑟𝑘 = 0.5 × (𝑃1(𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐−𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐) + 𝑃2(𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐−𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐) ) × 𝛥𝑉,

where 𝛥𝑉 = 𝑉2 − 𝑉1 , 𝑃1 and 𝑃2 are the corresponding ventricular pressures at
ventricular volume 𝑉1 and 𝑉2
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CHAPTER 4:
SPECIFIC AIM 1

The pulsatile flow loop was constructed to mimic the physiological flow in the
left side of the human heart. The CO of approximately 5 L/ min was achieved by
supplying the compressed air at 25 psi. The aortic and ventricular pressure waveforms
matched the physiological values approximately.

Flowrate waveform
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Figure 26: Flowrate waveform generated by the pulsatile flow loop.
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1

The average and the instantaneous flowrate generated by the flow loop was in
good agreement with the physiological values [81]. Figure 26 shows the flow rate
waveform spanned over one cardiac cycle. The maximum flow rate was 22.7 ± 1.73
L/min while the minimum flow rate was -3.0 ± 0.32 L/min. The flow loop could generate
and maintain a physiological CO of 5.0 ± 0.18 L/min.

4.2

Pressure waveforms and mean arterial pressure
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Figure 27: Ventricular and aortic pressure waveform ensemble averaged over
30 cardiac cycles.

Aortic and ventricular pressure waveforms (Figure 27) generated by the flow
loop, approximated the physiological pressure waveforms. The systolic ventricular and
aortic pressures peaked over 150 mmHg. The ventricular pressure peaked at 163 ± 3.82
mmHg and the aortic pressure was 159 ± 2.91/ 56 ± 1.23 mmHg. However, the mean
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arterial pressure (MAP) generated by the loop, which is the average arterial pressure
over a cardiac cycle [86], was found to lie within the physiological range of 70 to 110
mmHg [85]. The MAP was evaluated as:

𝑀𝐴𝑃 = 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 +

(𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 − 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒)
3

The MAP generated by the pulsatile flow loop was 90 mmHg.

4.3

Systolic diastolic duration
The systolic duration for the cardiac cycle, can be defined as the interval between

the onset of the left ventricular pressure rise and closing of the aortic valve (the icisural
notch observed in the aortic pressure waveform) [87]. Based on this definition, the flow
loop generated a 0.35 seconds long systole. Thus, the cardiac cycle (0.86 seconds) had a
systolic duration of 0.35 seconds which implied a diastolic duration of 0.51 seconds.
This resulted in a systolic diastolic (S/D) ratio of 0.7 which lies within the clinically
measured range of S/D ratio [88]
Although the ventricular and aortic pressure waveforms were an approximate of
the physiological waveforms, the flow loop could still generate a flowrate waveform and
a cardiac output which was in good agreement with physiological values. The MAP and
S/D ratio were well within its defined physiological range. These results implicate that
the flow loop could generate flow within the physiological parameters
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4.4

Discussion
The target of this aim was to construct and validate the pulsatile flow loop that

could replicate physiological flow conditions in the aortic valve and AA. The flow loop
was tuned by adjusting the compressed air that enabled to generate flow within the
physiological range of -5 to 20 L/min and a CO of approximately 5 L/min. The aortic
pressure was adjusted to match the physiological values by altering the resistance and
compliance, but the aortic pressure peak showed a higher value compared to the
physiological waveform even after altering the compliance and the resistance of the loop.
MAP calculated from the aortic pressures values, however lied within the physiological
range of 70 and 110 mmHg. The S/D ratio also was well within its physiological limits.
Thus, the flow loop was able to generate a flow rate, MAP and cardiac cycle with S/D
ratio that lied within the physiological parameters
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CHAPTER 5:
SPECIFIC AIM 2
This aim characterized the effect of valvular stenosis on flow dynamics in the
proximal and the distal ascending aorta (PAA and DAA, respectively). The pulsatile flow
loop and PIV setup described in sections 3.1 and 0 respectively, were used to capture the
ensemble-averaged velocity fields in the region of interest. A normal TAV (nTAV) and
two calcified TAVs (mTAV and sTAV) were used to quantify the impact of the degree of
stenosis on the instantaneous ensemble-averaged velocity, vorticity, turbulent kinetic
energy, viscous shear stress (VSS) and Reynolds shear stress (RSS) fields. The flow was
investigated during the acceleration phase, at peak systole, during the deceleration phase
and early diastolic phase.

5.1

Velocity Field
Ensemble-averaged velocity fields at four phases of the cardiac for all three valve

models are shown in Figure 28. During the acceleration phase, all the valve models
generated forward flow with distinctive jet structures in the proximal ascending aorta
(PAA) and the distal ascending aorta (DAA). In the PAA, the nTAV generated a wide
symmetric low velocity jet, while the reduced valve orifice of the mTAV and sTAV
caused an increase jet velocity in the PAA. The sTAV resulted in an abnormally high
velocity jet in the PAA, while relatively low velocities were observed in the distal region
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for all the valve models during this phase. A high velocity jet in PAA and a low velocity
jet in the DAA was observed for the sTAV. This variation in the velocity existing
amongst the two regions (proximal and distal) downstream of the sTAV, can be reasoned
with the high velocity jet falling out of the plane of observation in the DAA. At peak
systole, the nTAV generated lowest velocity of all the three valve models. The mTAV
and sTAV generated a 37% and 117 % increase in velocity, respectively when compared
to nTAV. A drop in the velocity was observed during the deceleration phase downstream
of the nTAV, while the mTAV and sTAV continued to demonstrate high velocity jets in
the DAA and the PAA, respectively. During early diastole, the valve shut close and no
significant flow structures were observed in any valve model. The fluid velocities
remained close to zero during this phase.
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Table 2: Peak velocity data in the AA during the acceleration phase, at peak systole,
during the deceleration phase and during early diastole
PAA

nTAV

mTAV

sTAV

Acceleration

1.2 m/s

1.8 m/s

4.16 m/s

Peak systole

2.3 m/s

3.3 m/s

5.0 m/s

Deceleration

1.9 m/s

2.09 m/s

3.19 m/s

Diastole

0.16 m/s

0.30 m/s

0.33 m/s

DAA

nTAV

mTAV

sTAV

Acceleration

1.15 m/s

1.69 m/s

0.9 m/s

Peak systole

1.7 m/s

2.98 m/s

1.04 m/s

Deceleration

1.39 m/s

2.28 m/s

0.87 m/s

Diastole

0.06 m/s

0.41 m/s

0.22 m/s
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Figure 28: Ensemble-averaged velocity fields captured for nTAV, mTAV and sTAV
valve models (left to right in order) in the PAA (proximal ascending aorta) and the
DAA (distal ascending aorta) region.
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5.2

Vorticity Field
Figure 29 shows the ensemble-averaged out-of-plane vorticity fields at four

phases of the cardiac cycle for all three valve models. The red and blue colors indicate
counterclockwise and clockwise vorticity, respectively. The highest magnitude of
vorticity was found along the edges of the jet emanating from the valves. All three valve
models produced counterclockwise (positive rotation) vorticity near the convexity of the
AA, while clockwise (negative rotation) vorticity was observed near the concavity. The
nTAV model generated the lowest magnitude of vorticity during the acceleration phase,
when compared to the stenosed valve models. This trend continued at peak systole, as the
mTAV and sTAV had vorticity magnitude 56% and 200% more than the nTAV. The
nTAV model exhibited shear layers around the edge of the orifice jet that were both
symmetrical and parallel to the axis of the valve in the PAA and the DAA. In contrast,
the mTAV and sTAV generated asymmetric vorticity patterns. The deceleration phase
was characterized by the same vorticity patterns as those observed at peak systole but
with reduced magnitude. Vorticity magnitude was relatively low at diastole for all the
three valve models, when compared with other phases.
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Table 3: Ensemble-averaged vorticity data captured during the acceleration phase, at peak
systole, during the deceleration phase and during early diastole
PAA

nTAV

mTAV

sTAV

Acceleration

498 s-1

870 s-1

2795 s-1

Peak systole

1165 s-1

1816 s-1

3493 s-1

Deceleration

578 s-1

944 s-1

2479 s-1

Diastole

115.8 s-1

253.4 s-1

435 s-1

DAA

nTAV

mTAV

sTAV

Acceleration

519 s-1

702 s-1

724 s-1

Peak systole

732 s-1

1176 s-1

826 s-1

Deceleration

542 s-1

656 s-1

673 s-1

Diastole

107 s-1

284 s-1

270 s-1
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Figure 29: Ensemble-averaged vorticity fields captured for nTAV, mTAV and sTAV
valve models (left to right in order) in the PAA (proximal ascending aorta) and the
DAA (distal ascending aorta) region.
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5.3

Viscous and Reynolds Shear Stress Fields
The distributions of viscous shear stress (VSS) at four phases of the cardiac cycle

for all three valve models is shown in Figure 30. The VSS plots exhibit some similarities
with the vorticity plots, as the regions of maximum shear stress are found along the edges
of the jet. This phenomenon is expected as the highest velocity gradients are found near
the regions of flow separation. Low VSS magnitude was associated with nTAV
throughout the cardiac cycle. However, a noticeable difference between the VSS fields
was observed amongst the stenosed valves during the acceleration phase. Elevated VSS
dominated the DAA and PAA downstream of the mTAV and sTAV, respectively. A
similar trend was observed at peak systole, but with higher VSS magnitude. The reduced
valve orifice produced by the mTAV and sTAV led to the narrowing of the jet, causing a
150% increase in VSS for mTAV and 216% increase for sTAV, relative to the nTAV.
During the deceleration phase, regions of high VSS continued to occupy the mTAV DAA
and sTAV PAA. VSS values were low for all valve models during diastole.
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Table 4: Ensemble-averaged VSS data captured during the acceleration phase, at peak
systole, during the deceleration phase and during early diastole.
PAA

nTAV

mTAV

sTAV

Acceleration

0.21 N/m2

0.44 N/m2

2.8 N/m2

Peak systole

1.04 N/m2

2.6 N/m2

3.2 N/m2

Deceleration

0.41 N/m2

0.43 N/m2

2.0 N/m2

Diastole

0.01 N/m2

0.03 N/m2

0.08 N/m2

DAA

nTAV

mTAV

sTAV

Acceleration

0.23 N/m2

0.31 N/m2

0.66 N/m2

Peak systole

0.54 N/m2

1.12 N/m2

1.02 N/m2

Deceleration

0.19 N/m2

0.39 N/m2

0.56 N/m2

Diastole

0.02 N/m2

0.017 N/m2

0.11 N/m2
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Figure 30: Ensemble-averaged VSS fields captured for nTAV, mTAV and sTAV valve
models (left to right in order) in the PAA (proximal ascending aorta) and the DAA (distal
ascending aorta) region.
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Figure 31 shows the Reynolds shear stress (RSS) fields for all three valve models
at four phases of the cardiac cycle. Irrespective of the degree of stenosis, the two stenosed
valve models generated peak RSS values two-orders of magnitude greater than the peak
VSS, thus it can be deduced that the flow was dominated by turbulent stresses. These
turbulent effects were more prominent in the wake of the valve leaflets where the
turbulence and velocity fluctuations attained their maximum. During the acceleration
phase, significant differences were observed, nTAV had relatively low RSS magnitude
throughout the AA, whereas the convexity of mTAV DAA and sTAV PAA featured 92%
and 267% increase in RSS magnitude, respectively when compared with the nTAV. At
peak systole, nTAV had a maximum RSS value of 165 N/m2 while mTAV and sTAV
showed a 39 % and 200 % increase, respectively. During the deceleration phase, high
RSS regions were still prevalent in the mTAV DAA, while very low velocity fluctuations
were measured throughout the nTAV AA. The diastolic phase did not exhibit any
substantial difference in RSS between the valve models and was characterized with very
low RSS magnitude for all the valve models, when compared to other phases.
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Table 5: RSS data captured during the acceleration phase, at peak systole, during the
deceleration phase and during early diastole

PAA

nTAV

mTAV

sTAV

Acceleration

85 N/m2

163 N/m2

307 N/m2

Peak systole

165 N/m2

230 N/m2

502 N/m2

Deceleration

108 N/m2

120 N/m2

250 N/m2

Diastole

3.24 N/m2

3.0 N/m2

5.4 N/m2

DAA

nTAV

mTAV

sTAV

Acceleration

86 N/m2

225 N/m2

70 N/m2

Peak systole

98 N/m2

203 N/m2

105 N/m2

Deceleration

71.6 N/m2

170 N/m2

82 N/m2

Diastole

2.15 N/m2

5.2 N/m2

4.3 N/m2
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Figure 31: Ensemble-averaged RSS fields captured for nTAV, mTAV and sTAV
valve models (left to right in order) in the PAA (proximal ascending aorta) and the
DAA (distal ascending aorta) region.
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5.4

Turbulent Kinetic Energy
Turbulent Kinetic Energy (TKE) fields at four phases of the cardiac cycle for all

three valve models are shown in Figure 32. Following the trend observed with the RSS
distribution, the nTAV resulted in the lowest TKE. A sharp increase in TKE was
observed near the convexity of the mTAV DAA during the acceleration phase. The sTAV
model showed similar characteristics in the PAA. While valvular stenosis generated up to
300% increase in TKE relative to the nTAV, at peak systole; the affected region
depended upon the degree of stenosis. The mTAV caused 113 % increase in DAA
relative to nTAV. sTAV generated high TKE values close to the valve leaflets in the
PAA, a 286 % increase, when compared to nTAV. During the deceleration phase, the
stenosed valves continued to generate high TKE, while low TKE was observed for all the
valve models during diastole.
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Table 6: TKE data captured during the acceleration phase, at peak systole, during the
deceleration phase and during diastole.

PAA

nTAV

mTAV

sTAV

Acceleration

0.59 m2/s2

0.96 m2/s2

1.02 m2/s2

Peak systole

1.45 m2/s2

1.2. m2/s2

5.6 m2/s2

Deceleration

0.51 m2/s2

0.5 m2/s2

1.44 m2/s2

Diastole

0.02 m2/s2

0.02 m2/s2

0.05 m2/s2

DAA

nTAV

mTAV

sTAV

Acceleration

0.33 m2/s2

1.31 m2/s2

0.37 m2/s2

Peak systole

0.43 m2/s2

3.2. m2/s2

0.84 m2/s2

Deceleration

0.31 m2/s2

0.97 m2/s2

0.34 m2/s2

Diastole

0.017 m2/s2

0.18 m2/s2

0.13 m2/s2
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Figure 32: Ensemble-averaged TKE fields captured for nTAV, mTAV and sTAV valve
models (left to right in order) in the PAA (proximal ascending aorta) and the DAA (distal
ascending aorta) region.
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5.5

Effective orifice area
The effective orifice area for all three valve models were calculated using the

Gorlin equation mentioned in 1.4.2.1 Diagnosis. The calculated EOA for all the three
valve models were 2.21 cm2 for the nTAV model (normal TAV), 1.18 cm2 for the mTAV
model (moderately stenosed valve model) and 0.69 cm2 for sTAV (severely stenosed
valve model).
The effective orifice area calculated from the PIV images for the nTAV model
was 2.01 cm2, for the mTAV model was 1.28 cm2 and for the sTAV was 0.72 cm2. The
area was calculated at the location of vena-contracta for all the three valve models. The
effective orifice area was evaluated from the velocity jets observed in the velocity field
obtained from PIV.

nTAV
mTAV
sTAV
The values of effective orifice are calculated for all the three valve models were
within the range defined for calcific aortic stenosis by AHA statistics.
5.6

Discussion
The goal of this aim was to study the effect of valvular stenosis on aorta

hemodynamics by implementing PIV to characterize the flow downstream of the normal
aortic valve model nTAV, and its stenosed counterparts, mTAV and sTAV. In this aim,
the hemodynamics in the proximal and the distal region of the AA, across the three valve
models were compared using ensemble averaged velocity, vorticity, viscous shear stress,
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Reynolds shear stress and turbulent kinetic energy fields at acceleration, peak systole,
deceleration and early diastolic phases of the cardiac cycle.
This study used a common aorta phantom for all the three valve models which
allowed to evaluate and seclude the impact of aortic valve stenosis on aorta
hemodynamics. The reduced valve orifice for the stenosed valve models generated
hemodynamic alterations which were characterized by elevated jet velocities. The sTAV
with the highest degree of stenosis was associated with the maximum jet velocity out of
the two stenosed valve models. This observation implies that the magnitude of jet
velocity was highly dependent on the severity of stenosis. These findings were in line
with the previous invitro, and computational studies that studied the impact of stenosis
over valvular flow [63], [64], [89]. The nTAV model showed a jet like flow in the
ascending aorta. However, the flow was more of three dimensional in case of stenosed
valve models. This is observed in case of sTAV model where the three-dimensional
characteristic of the jet caused it to fall out of the plane of the measurement. The
dependence of hemodynamic alterations over the degree of stenosis was observed for all
the flow metrics. Vorticity and VSS magnitudes were relatively higher downstream of the
stenosed valve models, when compared to the healthy one. Regions of elevated VSS were
present in both the convexity and concavity of the AA. This suggested that the regions of
elevated VSS corresponded to the symmetric dilation pattern associated with TAV AA.
High VSS was prevalent in the stenosed valve flow filed not only for the peak systole but
also during the acceleration and the deceleration phase of the cardiac cycle. This
highlight the fact that the aortic wall was exposed to higher VSS for a longer duration in
case of stenosed valve models, when compared to normal valve.in a cardiac cycle. The
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degree dependent characteristic of VSS were also found to match the findings of the
previous MRI and invitro studies [64], [90], [91]
The intensity of fluctuations in the flow filed was characterized in terms of TKE
and RSS which are both evaluated using fluctuating components of velocities. Both TKE
and RSS were dependent on the severity of stenosis, with the maximum values associated
with the severely stenosed valve.
The effective orifice area calculated using Gorlin equation for this study
approximated the effective orifice area measured from the flow images, captured using
particle image velocimetry. This implies that stenosed valve models designed using
commissural fusion could generate stenosis with effective orifice area equal to the values
calculated mathematically. These calculated and measured effective orifice areas for all
the three valve models were within the clinically defined physiological ranges.
Overall these results have demonstrated that valvular stenosis significantly altered
the flow downstream of the stenosed valves in the AA when compared to normal aortic
valve. The results also show that these flow abnormalities were concentrated in the
regions prone to dilation in CAS aortopathy. In vivo studies have associated elevated wall
shear stress in the AA with aortic stenosis using magnetic resonance imaging and thus
support the finding of this study [90], [91]. Shear stresses alterations in the AA can result
in abnormal biological responses from aorta wall endothelium leading to progressive
tissue alterations, aorta wall remodeling with possible dilation and dissection. In vivo
studies subjecting endothelial cells to chronic shear stress support this claim [92]. These
observations provide increasing evidence for the involvement of hemodynamics in the
stenosis associated aortopathy. These results isolate the impact of CAS on aorta flow in a
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non-dilated compliant silicon aorta model. The results demonstrate the impact of CAS on
AA hemodynamics in regions prone to dilations providing more evidence to the existence
of hemodynamic pathway in CAS aortopathy. These hemodynamic alterations could
cause adverse biological response from the aortic wall leading a positive feedback cycle
and accelerating disease progression. These observations suggest that there is a need to
further investigate the effects of flow abnormalities on aorta wall biology. Thus
histopathological studies should be performed in future to assess the impact of these
hemodynamic alterations on aortic tissue.
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CHAPTER 6:
SPECIFIC AIM 3
This aim evaluated the effect of valvular stenosis on left ventricular (LV)
function. Due to impaired leaflet motion and narrowed valvular orifice, the blood flow is
restricted. To maintain the same CO, the left ventricle must perform additional work.
This overload imposed by a stenosed valve on the left ventricle is evaluated in this aim.
6.1

Ventricular work
The pressure-volume (PV) graphs (Figure 33) were plotted and the left ventricular

work for each valve model was calculated by evaluating the area under its associated PV
curves.
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Figure 33: Figure shows the pressure-volume graphs for all three valve
models: nTAV, mTAV and sTAV.
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Figure 34: Bar graph showing left ventricular work associated with each
of the valve models: nTAV, mTAV and sTAV
An increase in the ventricular pressure was observed for each of the stenosed
valve models. The peak systolic pressure for mTAV was approximately 175 mmHg while
that for sTAV was around 200 mmHg.

As shown in the Figure 34, the nTAV was associated the lowest amount of ventricular
work. The introduction of valvular stenosis caused ventricular overload of 16% for the
mTAV and 27 % for the sTAV, when compared with the normal valve.

6.2

Discussion
This aim evaluated the amount of work, the LV does to maintain the physiological

cardiac output in case of valvular stenosis. In CAS, the aortic valve undergoes structural
changes in the form of leaflet stiffening, reduced valve orifice and impaired leaflet
motion generating obstruction to the blood flowing in to the aorta. To overcome this
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obstruction and maintain the CO, the ventricle is subjected to an overload. In this study
valvular stenosis, imposed up to 27 % of overload on the left ventricular. The amount of
ventricular overload increased with the severity of stenosis. Clinical studies have shown
ventricular overload to increase LV mass and wall thickness, causing LV hypertrophy
and heart failure [93]. Thus, the results of this aim demonstrate the association of aortic
stenosis with LV overload, and its impact on LV function in a degree dependent manner.
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CHAPTER 7:
CONCLUSION
CAS is a slow progressive disease characterized by reduced valve orifice and
impaired leaflet motion of the aortic valve and has been associated with aortopathy and
left ventricular dysfunction. This in vitro study isolated the impact of the degree of
valvular stenosis on left ventricular workload and aorta hemodynamics. The results of
this study demonstrated 1) altered hemodynamics in the aorta in case of stenosed valves,
2) excess ventricular workload imposed due valvular stenosis. Stenosis resulted in
regions of elevated velocity, shear stress and turbulence at locations prone to dilation in
the aorta, providing additional evidence to the hemodynamic theory of CAS associated
aortopathy. The excess ventricular work in case of the stenosed valves explain the
association of ventricular hypertrophy with aortic stenosis. The findings of this study thus
explain the susceptibility of CAS patients to aortopathy and heart failure.
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CHAPTER 8:
LIMITATIONS
This study had considerable limitations that requires attention. The PIV setup
allowed to capture the flow in 2-dimensions, while a 3-dimensional flow field would
have provided better understanding of the flow structures downstream of the aortic valve.
This limitation might explain the drastic change in the velocity amongst the proximal and
distal sections of sTAV aorta, since the high velocity jet was oriented outside the span of
the 2-dimensional measurement plane in the distal region. However, this did not halter
the study from demonstrating significant flow differences that existed downstream of the
three valve models. The near wall flow characteristics could not be characterized using
PIV due to non-homogenous seeding near the wall as the particles tend to move away
from the wall. The aortic and ventricular pressures generated by the flow loop
approximated the physiological values. This can be linked to the insufficiency of the flow
loop to mimic the systemic compliance and resistance. The cardiac output and the
instantaneous flow rate generated by the flow loop, however were well within the
physiological limits. Porcine aortic valve models were used in this study and valvular
stenosis was modelled using commissural fusion. The reliability of this method to mimic
stenosis was questionable because the artificial reduction created in the valve orifice to
model stenosis was heavily idealized based on trial and error. However, the downstream
flow velocity in the aorta and the transvalvular pressure gradient obtained from the PIV
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post processing and pressure transducers respectively, lied well within the AHA statistics
for aortic stenosis.
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